FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318945467> ?p ?o ?g. }

• W4318945467 endingPage "E98" @default.
• W4318945467 startingPage "E97" @default.
• W4318945467 abstract "We appreciate the interest in and discussion by Heinemann and colleagues of our recent AASLD Practice Guidance on primary sclerosing cholangitis (PSC) and cholangiocarcinoma.1 Indeed, we believe that living donor liver transplantation (LDLT) remains a promising option for PSC patients who might not otherwise have access to deceased donor liver transplantation (LT). Heinemann et al.2 queried the European Liver Transplant Registry (ELTR) and found that survival in adults and children with PSC was significantly lower after LDLT compared with deceased donor LT. They also found that LDLT recipients were at increased risk of biliary complications and recurrent PSC. These findings are intriguing and important; however, the analysis was not performed on an intention-to-treat basis and, therefore, does not account for the waitlist dropout of PSC patients awaiting deceased donor LT. In addition, the LT programs represented in the ELTR are low LDLT volume programs and LDLT volume has been associated with outcomes, including recipients undergoing LDLT for autoimmune hepatitis or cholestatic liver disease at high LDLT volume centers who had a significantly lower risk of graft failure than those transplanted at low LDLT volume centers.3 Furthermore, data from the Adult to Adult Living Donor Liver Transplantation (A2ALL) Cohort demonstrated a similar risk of recurrent PSC for recipients of either LDLT or deceased donor LT, with excellent overall survival despite recurrence.4 Finally, one of the authors (Gonzalo Sapisochin) has observed that at their high LDLT volume transplant center outcomes for PSC patients who have a potential living donor are better compared with those without a living donor option on an intention-to-treat basis (Gonzalo Sapisochin). Unlike other liver disease etiologies such as hepatitis C–associated or alcohol-associated liver disease, PSC patients tend to maintain hepatocellular synthetics function until very late stages of the disease. As a result, patients with PSC tend to have comparatively low Model for End-stage Liver Disease scores, dependent primarily on bilirubin elevation associated with recurrent cholangitis and jaundice. In this context, biological Model for End-stage Liver Disease of PSC patients may not accurately reflect the candidate’s risk of death on the waitlist. Although stratified by disease type, a recent study from Jackson et al.5 demonstrated that LDLT offers a substantial survival benefit to patients with end-stage liver disease even at Model for End-stage Liver Disease–Sodium scores as low as 11 compared with those who remained on the waitlist. This provides even more evidence to encourage LDLT for patients with PSC, especially in low Model for End-stage Liver Disease patients. There is no treatment to alter PSC’s natural history; so, disease progression is anticipated. Moreover, while the timing of overall disease progression varies, PSC patients may experience many severe symptoms, such as fatigue and pruritus, that significantly impact health-related quality of life. All studies of LT in PSC are limited by small sample sizes, wide variability in patient characteristics, and differing definitions of recurrent PSC. Differences in outcomes after LT across studies may also be skewed by referral and selection biases, variable access to LDLT, and clinical experience. We agree that more studies are needed to determine rates of recurrent PSC in patients receiving LDLT and the factors impacting recurrence rates and outcomes." @default.
• W4318945467 created "2023-02-03" @default.
• W4318945467 creator A5000789082 @default.
• W4318945467 creator A5004770797 @default.
• W4318945467 creator A5006827585 @default.
• W4318945467 creator A5012936802 @default.
• W4318945467 creator A5015556921 @default.
• W4318945467 creator A5016152531 @default.
• W4318945467 creator A5020017677 @default.
• W4318945467 creator A5025092611 @default.
• W4318945467 creator A5035435509 @default.
• W4318945467 creator A5047432843 @default.
• W4318945467 creator A5055239319 @default.
• W4318945467 creator A5087832439 @default.
• W4318945467 date "2023-01-03" @default.
• W4318945467 modified "2023-10-16" @default.
• W4318945467 title "Reply: Living donor liver transplantation for people with PSC" @default.
• W4318945467 cites W1987153020 @default.
• W4318945467 cites W2461027708 @default.
• W4318945467 cites W3203676558 @default.
• W4318945467 cites W4289711212 @default.
• W4318945467 doi "https://doi.org/10.1097/hep.0000000000000210" @default.
• W4318945467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36732294" @default.
• W4318945467 hasPublicationYear "2023" @default.
• W4318945467 type Work @default.
• W4318945467 citedByCount "0" @default.
• W4318945467 crossrefType "journal-article" @default.
• W4318945467 hasAuthorship W4318945467A5000789082 @default.
• W4318945467 hasAuthorship W4318945467A5004770797 @default.
• W4318945467 hasAuthorship W4318945467A5006827585 @default.
• W4318945467 hasAuthorship W4318945467A5012936802 @default.
• W4318945467 hasAuthorship W4318945467A5015556921 @default.
• W4318945467 hasAuthorship W4318945467A5016152531 @default.
• W4318945467 hasAuthorship W4318945467A5020017677 @default.
• W4318945467 hasAuthorship W4318945467A5025092611 @default.
• W4318945467 hasAuthorship W4318945467A5035435509 @default.
• W4318945467 hasAuthorship W4318945467A5047432843 @default.
• W4318945467 hasAuthorship W4318945467A5055239319 @default.
• W4318945467 hasAuthorship W4318945467A5087832439 @default.
• W4318945467 hasBestOaLocation W43189454671 @default.
• W4318945467 hasConcept C126322002 @default.
• W4318945467 hasConcept C141071460 @default.
• W4318945467 hasConcept C2777075537 @default.
• W4318945467 hasConcept C2779134260 @default.
• W4318945467 hasConcept C2779609443 @default.
• W4318945467 hasConcept C2780615123 @default.
• W4318945467 hasConcept C2911091166 @default.
• W4318945467 hasConcept C2991966547 @default.
• W4318945467 hasConcept C71924100 @default.
• W4318945467 hasConcept C72563966 @default.
• W4318945467 hasConcept C90924648 @default.
• W4318945467 hasConceptScore W4318945467C126322002 @default.
• W4318945467 hasConceptScore W4318945467C141071460 @default.
• W4318945467 hasConceptScore W4318945467C2777075537 @default.
• W4318945467 hasConceptScore W4318945467C2779134260 @default.
• W4318945467 hasConceptScore W4318945467C2779609443 @default.
• W4318945467 hasConceptScore W4318945467C2780615123 @default.
• W4318945467 hasConceptScore W4318945467C2911091166 @default.
• W4318945467 hasConceptScore W4318945467C2991966547 @default.
• W4318945467 hasConceptScore W4318945467C71924100 @default.
• W4318945467 hasConceptScore W4318945467C72563966 @default.
• W4318945467 hasConceptScore W4318945467C90924648 @default.
• W4318945467 hasIssue "5" @default.
• W4318945467 hasLocation W43189454671 @default.
• W4318945467 hasLocation W43189454672 @default.
• W4318945467 hasOpenAccess W4318945467 @default.
• W4318945467 hasPrimaryLocation W43189454671 @default.
• W4318945467 hasRelatedWork W19370246 @default.
• W4318945467 hasRelatedWork W1984016671 @default.
• W4318945467 hasRelatedWork W2003939476 @default.
• W4318945467 hasRelatedWork W2030443451 @default.
• W4318945467 hasRelatedWork W2050945564 @default.
• W4318945467 hasRelatedWork W2098906779 @default.
• W4318945467 hasRelatedWork W2222377009 @default.
• W4318945467 hasRelatedWork W391393365 @default.
• W4318945467 hasRelatedWork W4239890390 @default.
• W4318945467 hasRelatedWork W4319456916 @default.
• W4318945467 hasVolume "77" @default.
• W4318945467 isParatext "false" @default.
• W4318945467 isRetracted "false" @default.
• W4318945467 workType "article" @default.